Clinical Trials & Research

INO-4800 was shown to be safe, well-tolerated and immunogenic in all age groups Phase 2 results informed INOVIO’s selection of 2.0 mg dose for the Phase 3 segment of the trial Data published as a preprint in MedRxiv PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to
0 Comments
A leading South Australian immunologist has been awarded $3 million from the Federal Government to accelerate work on a locally developed Covid-19 vaccine, in what’s anticipated to be the second line of defence against the virus. Professor John Hayball is a researcher at the University of South Australia and Chief Scientific Officer at Adelaide biotechnology
0 Comments
May 10, 2021 — Today, the U.S. Food and Drug Administration expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age. The FDA amended the EUA originally issued
0 Comments
A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal coronavirus disease 2019 (COVID-19) vaccine in mice. Their analyses reveal that a single dose of the vaccine is capable of inducing both neutralizing and
0 Comments
TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE) May 08, 2021 –New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC), showed preliminary response and disease control in patients with metastatic triple negative breast cancer (TNBC) with disease progression following standard treatment.
0 Comments
Countries like the UK, Israel, and the USA are now in the thick of successful vaccine campaigns against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic. As the vaccine rollout continues, there have been thousands of anecdotal reports of receivers suffering symptoms of mild fatigue, achiness, and fever in
0 Comments
PREVENT-19 clinical trial expanded to assess the efficacy, safety and immunogenicity of NVX-CoV2373 for the prevention of COVID-19 in up to 3,000 12-17-year-old adolescents President of Research and Development, Gregory Glenn, M.D., to provide update regarding the additional trial arm during World Vaccine Congress GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX),
0 Comments
It is now widely known that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), spreads via respiratory droplets. The persistence of the aerosol in the environment largely determines the success of the viral transmission. In addition, the virus-laden droplets can also deposit on various surfaces
0 Comments
Publication of initial primary analysis highlights NVX-CoV2373 cross-protection against B.1.351 variant prevalent in South Africa during study GAITHERSBURG, Md., May 5, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the initial primary analysis of a Phase 2b clinical trial
0 Comments
Black patients from disadvantaged neighborhoods were significantly more likely to die within five years of surviving a heart attack compared with Black heart attack patients from wealthier neighborhoods and white patients of any socioeconomic means who survive a heart attack, according to a study being presented at the American College of Cardiology’s 70th Annual Scientific
0 Comments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 30, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its COVID-19 vaccine to prevent COVID-19 in individuals 18 years of age and older. “We thank the WHO for their data review and for their issuance of
0 Comments
Last summer, Global Plasma Solutions wanted to test whether the company’s air-purifying devices could kill covid-19 virus particles but could find only a lab using a chamber the size of a shoebox for its trials. In the company-funded study, the virus was blasted with 27,000 ions per cubic centimeter. In September, the company’s founder incidentally
0 Comments
CARMIEL, Israel and BOSTON, April 28, 2021 /PRNewswire/ – Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced that they received
0 Comments
Changi General Hospital (CGH) and the Singapore University of Technology and Design (SUTD) have developed the Blood WArning Technology with Continuous Haemoglobin (BWATCH) sensor, a lightweight monitoring device placed over a patient’s bandage that detects real-time bleeding from wound sites following invasive medical procedures. BWATCH was tested and validated in an observational clinical trial involving
0 Comments
CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ – Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the New England Journal of Medicine (NEJM) has published the results of the global Phase 3 clinical program of vadadustat for the treatment of anemia due to chronic kidney disease
0 Comments
A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The team analyzed the impact of potential mutations in the spike receptor-binding domain (RBD) on antibody efficacy. The study is
0 Comments
NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced an update regarding the U.S. Food and Drug Administration (FDA) approval process for Epsolay (benzoyl peroxide) 5%
0 Comments
Root Sciences and Ecodyst have joined forces to provide hi-speed evaporators to the market for solvent recovery in cannabinoid applications. Solvent recovery is a common bottleneck in many cannabis processing operations. The unique line of products manufactured by Ecodyst provides single equipment solutions for solvent recovery, decarboxylation, and devolatilization to prepare crude oil for molecular
0 Comments
KENILWORTH, N.J., & MIAMI–(BUSINESS WIRE) April 15, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the clinical development program for molnupiravir (MK-4482/ EIDD-2801), an investigational orally available antiviral therapeutic. Based on a planned interim analysis of data from the Phase 2,
0 Comments
KENILWORTH, N.J.–(BUSINESS WIRE) April 15, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the treatment of hospitalized patients with COVID-19. Merck acquired MK-7110 in December 2020 through its acquisition of OncoImmune, a privately-held clinical-stage biopharmaceutical company.
0 Comments
DeNovix Inc. announces the launch of EasyApps Secure, a 21 CFR Part 11 Compliance Ready software option for the DS-11 Series range of microvolume spectrophotometers and fluorometers. The new suite of controls for EasyApps software enables regulated labs to securely generate results within their compliant workflow while retaining the trademark ease of use associated with
0 Comments
INDIANAPOLIS, April 16, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) has requested the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg alone. Lilly made this request due to the evolving variant landscape in the U.S. and the full availability of bamlanivimab and etesevimab together. This request
0 Comments
Several novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern have emerged since the inception of the pandemic. These variants often displaying enhanced infectiousness and virulence compared with wild-type strain. Whole genome sequencing is currently the gold standard in the identification and monitoring of these lineages. However, the set-up costs and operational requirements
0 Comments
April 16, 2021 — Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the
0 Comments
TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ — Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase 3 trial (2069B) of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COV™ (casirivimab with
0 Comments
Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer. Today’s approval is the first treatment in
0 Comments